Assessment of Atherosclerotic Plaque Characteristics Change by DCE-MRI With Alirocumab - a Pilot Study
Latest Information Update: 05 Nov 2021
Price :
$35 *
At a glance
- Drugs Alirocumab (Primary)
- Indications Atherosclerosis; Hypercholesterolaemia
- Focus Therapeutic Use
- 05 Apr 2021 According to ClinicalTrials.gov, the recruitment status of this study is unknown because the information has not been verified recently (last Verified April 2019 ).
- 24 Apr 2019 Planned End Date changed from 1 Feb 2019 to 1 Nov 2019.
- 24 Apr 2019 Planned primary completion date changed from 1 Dec 2018 to 1 Nov 2019.